Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
| ▸ | CD4 | P01730 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12626178 | 0.83 | KMT2A (0.56) | SMN1; SMN2LMNAFAAHMGLLCD4 | |
| SCHEMBL8210784 | 0.82 | CD4 (0.58) | SMN1; SMN2LMNAFAAHMGLLCD4 | |
| SCHEMBL4395431 | 0.79 | LMNA (0.44) | SMN1; SMN2LMNAFAAHMGLLCD4 | |
| SCHEMBL4393905 | 0.79 | SMN1; SMN2 (0.49) | GAASMN1; SMN2LMNAFAAHMGLL | |
| SCHEMBL10726957 | 0.79 | SMN1; SMN2 (0.58) | SMN1; SMN2LMNAFAAHMGLLCA2 | |
| SCHEMBL4383741 | 0.78 | SMN1; SMN2 (0.56) | GAASMN1; SMN2LMNAFAAHMGLL | |
| SCHEMBL4387319 | 0.78 | ALDH1A1 (0.47) | GAASMN1; SMN2LMNAFAAHMGLL | |
| SCHEMBL13995367 | 0.78 | LMNA (0.64) | GAASMN1; SMN2LMNAL3MBTL1ALDH1A1 | |
| SCHEMBL4381821 | 0.77 | LMNA (0.46) | SMN1; SMN2LMNAFAAHMGLLCD4 | |
| SCHEMBL4387781 | 0.77 | TSHR (0.44) | SMN1; SMN2LMNAFAAHMGLLCD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| EP-2040698-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008008398-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | GAA 3245/4885SMN1; SMN2 664/4885LMNA 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.